Ownership Submission
FORM 4
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
1. Name and Address of Reporting Person *
|
Dulac Edward J III
|
|
2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [FATE]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
|
_____ 10% Owner
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
Chief Financial Officer /
|
|
(Last)
|
(First)
|
(Middle)
|
C/O FATE THERAPEUTICS, INC. , 12278 SCRIPPS SUMMIT DRIVE
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
SAN DIEGO
|
CA
|
92131
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Dulac Edward J III
C/O FATE THERAPEUTICS, INC.
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO, CA92131
|
|
|
Chief Financial Officer
|
|
Signatures
/s/ Cindy Tahl, as Attorney-in-Fact
|
2022-08-19
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
(1)
|
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 10,000 shares of Common Stock underlying RSUs granted to the Reporting Person on August 17, 2020. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
|
(2)
|
Represents the weighted average sale price of the shares sold from $29.29 to $30.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.